Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116661 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT01116661 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 199 participants.
The verdict
NCT01116661, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain. On imaging, this accumulation of fluorescent porphyrins helps delineate tumor borders, resulting in the surgeon being better able to visualize and thus able to make a complete, or near-complete resection of the tumor.
Interventions
- DRUG 5-Aminolevuline Acid (ALA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2010-08 |
| Est. Completion | 2019-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01116661
The ClinicalTrials.gov registry entry for NCT01116661 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5-Aminolevuline Acid (ALA) is the first listed.
NCT01116661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01116661 about?
NCT01116661 is a clinical study titled "Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain". The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain. On imaging, this accumulation of fluorescent porphyrins helps delineate tumor borders, resulting in the surgeon being better able to ...
What is the current status of trial NCT01116661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2010-08. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT01116661?
The interventions under investigation include: 5-Aminolevuline Acid (ALA) (DRUG).
Who is sponsoring clinical trial NCT01116661?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.